IBI-3010

N/A

Report date: 2025/06/04 14:33:21

Base Information

Drug NameIBI-3010

Drug Alias NameIBI3010IBI-3010

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > NT1 payload

Mechanisms of ActionDNA topoisomerase I inhibitorsAnti-FOLR1

TargetsDNA topoisomerase IFolate receptor alpha

Therapy Area/IndicationsSolid tumoursNeoplasm Metastasis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesInnovent Biologics(Suzhou) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursNeoplasm Metastasis

Inactive IndicationsN/A

Other Information

ATC CodeN/A